Next Article in Journal
Emerging Biomarker Potential of Extracellular Vesicle-Enclosed MicroRNAs for Liver Fibrosis Detection
Previous Article in Journal
Human Extravillous Trophoblasts Require SRC-2 for Sustained Viability, Migration, and Invasion
Previous Article in Special Issue
Microgliosis in the Spinal Dorsal Horn Early After Peripheral Nerve Injury Is Associated with Damage to Primary Afferent Aβ-Fibers
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cells
Volume 14
Issue 13
10.3390/cells14131022
cells-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Hyperalgesia in the Psychological Stress-Induced Fibromyalgia Model Shows Sexual Dimorphism Mediated by LPA1 and LPA3

by
Hiroshi Ueda
1,2,3,4,*,
Hiroyuki Neyama
1,5,
Naoki Dozono
1,2,
Junken Aoki
6 and
Jerold Chun
7
1
Department of Pharmacology and Therapeutic Innovation, Nagasaki University Institute of Biomedical Sciences, Nagasaki 852-8521, Japan
2
Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan
3
Laboratory for the Study of Pain, Research Institute for Production Development, Kyoto 606-0805, Japan
4
Graduate Institute of Pharmacology, National Defense Medical Center, Nei-hu, Taipei 114201, Taiwan
5
Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan
6
Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan
7
Center for Neurological Diseases, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA
*
Author to whom correspondence should be addressed.
Cells 2025, 14(13), 1022; https://doi.org/10.3390/cells14131022
Submission received: 12 May 2025 / Revised: 26 June 2025 / Accepted: 3 July 2025 / Published: 4 July 2025
(This article belongs to the Special Issue Molecular Mechanisms of Neuropathic Pain)
Browse Figures
Review Reports Versions Notes

Abstract

Since the initial report indicating that LPA1 signaling plays a key role in initiating nerve injury-induced neuropathic pain (NeuP), subsequent studies using knockout mice and LPA1/3 antagonists have demonstrated that LPA1 and LPA3 signaling impact NeuP and fibromyalgia (FM) models. In the present study, we identified hyperalgesia sexual dimorphism involving LPA1/3 signaling in the intermittent psychological stress induced-related FM-like model called intermittent psychological stress (IPS)-induced generalized pain (IPGP) model where the hyperalgesia in IPGP mice was abolished in LPA1- and LPA3-knock-out mice. Pharmacological intervention by intraperitoneal (i.p.) treatments with the LPA1/3 antagonist Ki16425 consistently prevented hyperalgesia. However, intracerebroventricular treatments with Ki16425 abolished hyperalgesia in male, but not female, mice. Notably, intrathecal treatments of Ki16425 did not prevent hyperalgesia. Further studies revealed that splenocytes derived from female IPGP mice could initiate hyperalgesia via adoptive transfer in naïve mice, and this effect was abolished when donor mice were pre-treated with Ki16425 (i.p.). Thus, these studies identify male-specific LPA1/3-mediated mechanisms in the brain underlying IPGP, as well as distinct LPA-LPA1/3-mediated peripheral immune mechanisms.

1. Introduction

Sexual dimorphism in chronic pain has increasingly been discussed in recent years [1,2,3,4]. Fibromyalgia (FM) is overwhelmingly female-dominant and sex differences remain an important issue. However, the full picture of FM mechanisms is still not fully clear. Here, we considered the involvement of lysophosphatidic acid (LPA, a bioactive lipid mediator) receptors. Previous studies using LPA receptor 1 (LPA1)-KO mice have revealed that pain-related phenotypes are completely abolished in animal models of pain [5,6,7], including the following: hyperalgesia in neuropathic pain (NeuP), such as partial sciatic nerve ligation (pSNL); chemotherapeutic agent paclitaxel-induced models; type-1 and type-2 diabetes-related models; the central poststroke pain model. Furthermore, the role of LPA and LPA1 signaling in NeuP, has also been reported in animal models of lumbar spinal canal stenosis [8], trigeminal ganglionic compression [9], and joint neuropathy [10,11]. In the NeuP model, intense and non-selective stress produced LPA and LPA synthesis was subsequently amplified in a feed-forward manner through the activation of LPA1 and LPA receptor 3 (LPA3) on microglia [6,7]. This mechanism provides evidence that LPA plays an important role in the formation of chronic pain. Interestingly, LPA production was found to increase even 2–3 weeks after pSNL [12] and continuous administration of LPA1/3 antagonists completely attenuated established chronic pain. These findings support LPA1/3 signaling as a significant component of pain memory. Thus, the inhibitors of LPA-LPA1 signaling have been considered as potential targets for the treatment of NeuP [13,14].
Multiple animal models for FM have been developed for the purpose of developing diagnostics and treatments, based on symptomatology and possible pathogenesis. These include the vagotomized rat model [15]; twice repeated muscular acid injection-induced generalized pain model (AcGP) [16]; intermittent cold stress (ICS)-induced generalized pain (ICGP) model [17]; intermittent sound stress model [18]; reserpine administration-induced model [19]; intermittent psychological stress (IPS)-induced generalized pain (IPGP) model [20,21]. Recently, we reported that both IPGP and ICGP models share similar pathophysiological and pharmacotherapeutic features, which are clinically found in FM patients [21]. Among these models, we found evidence that LPA1 signaling is involved in the mechanisms of IPGP, ICGP, and AcGP-type FM models, by using LPA1-KO mice, and treatment with LPA1-antagonists [20,21].
Although details of molecular and cellular mechanisms of NeuP and FM models through LPA1 signaling remain elusive, there are reports that microglial activation through LPA-LPA1 signaling plays a key role in NeuP, FM, and neuroinflammation [7,22,23,24,25,26,27]. Pioneering studies have also described a sexual dimorphism in the mechanisms of NeuP. They found that microglial cells are required for NeuP in male but not female mice, whereas T-cells are likely to be involved in female mice [28,29,30,31,32,33]. In the present study, we report the sexual dimorphism that LPA1 and LPA3 mechanisms are differentially involved in the brain and periphery, including splenic immunity, using FM models.

2. Materials and Methods

2.1. Animal Experiments

Male and female C57BL/6J mice (6–12 weeks old) from Japan SLC (Shizuoka, Japan) or TEXAM Corporation (Nagasaki, Japan), and homozygous mutant mice for the LPA1 receptor gene (LPA1-KO), and LPA3 receptor gene (LPA3-KO) weighing 20–25 g were used. Male and female homozygous mutant LPA1- and LPA3-KO mice were kindly provided by Prof. Jerold Chun, co-author. LPA1- and LPA3-KO mice had been backcrossed for 10 generations with C57BL/6J, which were used for wild-type mice to match genetic background. Whilst we backcrossed, homozygous mutant litter was confirmed by genotyping, as previously reported [34,35].
They were housed at 22 ± 2 °C and 55 ± 5% relative humidity with a 12 h light/dark cycle with a standard laboratory diet and water ad libitum. All experiments were conducted in accordance with the ethical guidelines of the Kyoto University Animal Research Committees (Approval number: 19-38), Nagasaki University Animal Research Committees (Approval number: 1607201325-8), and complied with the fundamental guidelines for the proper conduct of animal experiments and related activities in academic research institutions under the jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology, Japan. In addition, the present study has been performed to comply with ARRIVE guidelines [36]. For randomization, the mechanical pain thresholds of each animal were measured before experiments, and animals were assigned to the control and treatment groups, which had approximately equal pain thresholds. Investigators who oversaw the project, the experimental design, and the conduct of experiments were independent to achieve blinding. The total number of animals used in this study was 172.

2.2. IPGP and ICGP Model

For the IPGP model, mice were exposed to intermittent psychological stress (IPS) by using the communication box (CBX-9M, Muromachi-Kikai, Tokyo, Japan) that has nine compartments (10 cm × 10 cm) with divided transparent plastic walls. Physical electrical stress (120 times) was given to 5 mice through the grid floor by a shock generator (CSG-001, Muromachi-Kikai, Tokyo, Japan) and cycler timer (CBX-CT, Muromachi-Kikai, Tokyo, Japan). These mice were individually put in the compartment located at the center and 4 corners without cover, as previously reported [20,21]. For IPS, mice which were in the remaining 4 compartments with insulating plastic cover, were exposed to psychological stress through seeing, hearing, and smelling the foot-shocked mice. In all experimental paradigms, stress was given once per day for 5 days. The post-stress day 1 stands as P1. For ICGP, mice were exposed to intermittent cold stress (ICS) as previously described [17,21]. In this model, mice were kept in a room under the condition of 22 ± 2 °C and humidity of 60 ± 5%. During the stress period, two mice were kept in each cage (12 × 15 × 10.5 cm), and fed ad libitum with a standard laboratory diet and tap water. On the 1st day (or day 0), mice were kept in a cold room at 4 ± 2 °C from 16:30 PM. In the cold room, mice were placed on a stainless-steel floor to induce a rapid temperature change and covered with plexiglass cage. The next day, mice were removed at 10:00 AM (day 1), and kept at 24 ± 2 °C, leaving the stainless floor in the cold room. Thirty min later, mice were put back in the cold room for another 30 min. These processes were repeated until 16:30 PM, followed by the placement of mice in the cold room overnight. On the next day (day 2), the treatment of mice with alternate temperature change processes was performed again. Finally, on day 3 (or post-stress day 1/P1), mice were removed from the cold room at 10:00 AM, kept at room temperature for at least 1 h, and used for tests. When constant cold stress (CCS) was given for 3 days, mice also acquired hyperalgesia, but the hyperalgesia completely recovered within 5 days. This suggests that generalized and chronic pain induced by ICS is not simply attributed to the cold stress. There was no apparent skin damage after ICS or CCS.

2.3. Partial Sciatic Nerve Ligation (pSNL) Model

For the pSNL model, mice received a small skin incision exposing the right-side sciatic nerve. The dorsal half of the sciatic nerve at the upper thigh level was tightly ligated with a sterile silk suture (virgin silk thread-K, USP 9-0, Kono Seisakusho, Chiba, Japan), as previously described [12]. All procedures should be smoothly but carefully performed, minimizing systemic neuroinflammatory influences.

2.4. Pain Tests

In the mechanical paw pressure test, mice were acclimatized on a 6 mm × 6 mm wire-mesh grid floor for over 1 h. A mechanical stimulus was then applied to the middle of the hind paw plantar surface using a digital von Frey anesthesiometer, with a rigid tip of 0.8 mm in outer diameter (Model 2390, 90 g probe, IITC Inc., Woodland Hills, CA, USA), and a transducer indicator (Model 1601; IITC Inc., Woodland Hills, CA, USA). The mechanical paw withdrawal threshold was determined from the average of three trials of paw pressure. A cut-off pressure of 20 g was set to avoid tissue damage. In the electrical stimulation-induced paw withdrawal (EPW) test, on the other hand, electrodes of Neurometer® Current Perception Threshold/C (CPT/C; Neurotron Inc., Baltimore, MD, USA) were attached to the planter and insteps of the hind paw, and transcutaneous nerve stimuli with sine-wave pulses of 2000 Hz or 250 Hz were applied. The minimum intensity at which each mouse withdrew its paw (cutoff time: 3 s) was evaluated by nociceptive current threshold (μA), as described previously [21]. The in vivo patch-clamp recording studies using acutely isolated rat spinal cord slices characterized that transcutaneous stimuli at 2000 Hz and 250 Hz caused excitatory synaptic responses in the substantia gelatinosa neurons, which correspond to Aβ- and Aδ-fiber stimulation, respectively [37]. This method has an advantage that no acclimatization time is necessary since the experimenter holds the mouse.

2.5. Clodronate Liposome Treatments

To deplete peripheral macrophages, dichloromethylene diphosphonate (clodronate) encapsulated liposomes (0.05 mg/10 µL; HYGIEIA BIOSCIENCE, Osaka, Japan) or PBS vehicle control liposomes were administrated by i.p. injection at a volume of 200 μL/mouse, as previously described [38].

2.6. Isolation and Adoptive Transfer of Splenocytes

To investigate peripheral immunity contribution to hyperalgesia in female mice with IPGP, the adoptive transfer of splenocytes from a donor mouse into a naïve mouse was attempted on the analogy of previous studies [27,39]. The spleen was isolated from IPS-treated female mice at P19 and placed in 3 mL of ice-cold RPMI 1640 medium (Gibco, Grand Island, NY, USA) containing 2% fetal bovine serum (FBS), followed by mincing using the plunger of a 1 mL injection syringe. The cell suspension was filtrated through a 70 μm mesh-cell strainer, washed with 5 mL of ice-cold PBS containing 2% FBS, and incubated in 3 mL of red blood cell lysis buffer (Abcam, San Diego, CA, USA) for 3 min at room temperature. The reaction was stopped by adding 5 mL of ice-cold PBS containing 2% FBS, washed, and resuspended in 3 mL of the same buffer. An aliquot of the suspension (200 μL, 1 × 106 cells) was then injected into the right retro-orbital sinus (retro-orbital injection) of the naïve male mouse under isoflurane (4%) anesthesia [40,41].

2.7. Drug Treatments

LPA1/3 antagonist Ki16425 was dissolved in saline for the intraperitoneal (i.p.) injection (100 μL/10 g of body weight) or in the aCSF (125 mM NaCl, 3.8 mM KCl, 1.2 mM KH2PO4, 26 mM NaHCO3, 10 mM glucose, pH 7.4) for the intracerebroventricular (i.c.v., 5 μL) or intrathecal (i.t., 5 μL) injection. The i.c.v. injection was performed using the method from Haley and McCormick [42]. The i.t. injection was given into the space between spinal L5 and L6 segments according to the method described by Hylden and Wilcox [43].

2.8. Statistical Analysis

All data are shown as mean ± S.E.M. Statistical value was calculated by GraphPad Prism 8 (GraphPad Software Inc., La Jolla, CA, USA) with p value set at under 0.05. Sample size was decided by our previous reports [7]. Statistical differences between the group were analyzed using two-way repeated measures ANOVA followed by Bonferroni’s or Tukey’s multiple comparisons test. Individual statistics were presented in figure legends.

3. Results

3.1. Involvement of LPA3 Signaling in IPGP and ICGP Models in Male Mice

It has already been reported that LPA1 plays a key role in IPGP and ICGP models using male LPA1-KO mice. As shown in Figure 1A,B, male wild-type (WT) mice exhibited stable mechanical hyperalgesia from P1 to P22, after IPS induction from D1 to D5. Mechanical hyperalgesia was completely absent in male LPA3-KO mice with IPS treatment and LPA3-KO mice without IPS treatment. In addition to the equivalent pathophysiological and pharmacotherapeutic features between IPGP and ICGP models, a similar anti-hyperalgesia role of LPA1 [20] and LPA3 was found in the ICGP model (Figure 1C,D). Mechanical hyperalgesia was observed in male WT mice from P1 to P19 after ICS treatment. Male LPA3-KO mice, in contrast, did not show mechanical hyperalgesia, either with ICS treatment or without ICS treatment.
Next, male mice were administered the LPAR1/3 antagonist Ki16425 30 mg/kg (i.p.), once daily from P5 to P18 (Figure 1E). The IPGP-induced mechanical hyperalgesia reversed from P12 to P19 (Figure 1F). To test the noxious paw-withdrawal response (hypersensitivity), mice received a 2000 Hz current for non-noxious Aβ fibers, and 250 Hz current for noxious Aδ fibers generated by a Neurometer® [44]. The IPS-induced hypersensitivity at P1 and P5 was significantly reversed at P12 and P19 after repeated Ki16425 treatment (Figure 1G,H).

3.2. Involvement of LPA1 and LPA3 Signaling in the IPGP Model in Female Mice

IPS-induced pain remained stable until at least P19 in female WT mice (Figure 2B–D). In LPA1-KO mice with IPS, mechanical hyperalgesia was not observed at P1 and P5. In LPA3-KO mice, mechanical hyperalgesia was not observed at P1, but a reduction in paw withdrawal threshold occurred at P5 suggesting partial hyperalgesia suppression may occur, although without significance. When Ki16425 was administered continuously in WT mice from P5 to P18 (Figure 2A), mechanical hyperalgesia was significantly blocked at P12 and P19 (Figure 2B). Similar observations were also observed with Neurometer® stimulation experiments. LPA1-KO mice did not develop hypersensitivity at P1 and P5, evaluated by 2000 Hz and 250 Hz stimulation (Figure 2C,D). LPA3-KO mice did not show hypersensitivity at P1 with 2000 Hz stimulation but did display hypersensitivity at P5. At 250 Hz the anti-hypersensitivity effect was partial but significant at P1 and P5. Thus, the blocking of mechanical hyperalgesia and Neurometer hypersensitivity in LPA3-KO mice appears to be less evident than in LPA1-KO mice. Therefore, LPA3 may be more important in the early or developing stage of abnormal pain, but less so in the maintenance stage. When Ki16425 was i.p. administered, hypersensitivity to the stimulation with 2000 Hz and 250 Hz at P12 and P19 significantly decreased. The reversal of hypersensitivity was more evident at the later time point, P19.

3.3. Sex Differences in the Effect of Intracerebroventricular Administration of Ki16425

Next, Ki16425 at 10 nmol was administered intracerebroventricularly (i.c.v.) to male mice once daily from P5 to P11 (Figure 3A). At P12, IPS-induced mechanical hyperalgesia, and Neurometer hypersensitivity at 2000 Hz and 250 Hz were significantly blocked (Figure 3B–D). Surprisingly, Ki16425 (i.c.v.) administration to female mice showed no anti-hyperalgesia or anti-hypersensitivity effect (Figure 3E–G).

3.4. Lack of Blocking Effects on Hyperalgesia and Hypersensitivity by Intrathecal Administration of Ki16425

Ki16425 at 10 nmol was then intrathecally (i.t.) administered to male and female mice daily from P5 to P11 (Figure 4A). No effect in response to treatment was observed in mechanical hyperalgesia, or Neurometer hypersensitivity at 2000 Hz and 250 Hz, up until P12 (Figure 4B–G).

3.5. Lack of Blocking Effect of Clodronate Liposome on Female IPGP Model

It is known that i.p. treatment with clodronate liposome depletes peripheral macrophage to block neuropathic pain [38]. To evaluate effects of clodronate liposome treatment in the present study, liposomes containing 25 mg/kg of clodronate were given 30 min before and 6 days after the pSNL (Figure 5A,B). The mechanical hyperalgesia at the ipsilateral paw of male mice at P1 and P7 was abolished by clodronate liposome treatment (Figure 5C). The hypersensitivity evaluated by 2000 Hz and 250 Hz stimulation was also significantly reversed by clodronate liposome treatment (Figure 5D,E).
In the IPGP model in female mice, clodronate liposomes were given 30 min before the first day of IPS and after day 5 of IPS (Figure 5F,G). The mechanical hyperalgesia or Neurometer hypersensitivity evaluated by 2000 Hz and 250 Hz stimulation at P1 and P5 after IPS was not affected by clodronate liposomes (Figure 5H–J).

3.6. Blocking Effect of Ki16425 on the Induction of Pain Hypersensitivity by Splenocytes Derived from Female IPGP Model Mice

Next, splenocytes were prepared at P19 after the IPS in female mice and were then administered (i.v.) to naïve mice (Figure 6A,B). This induced significant mechanical hyperalgesia or electrical hypersensitivity evaluated by 2000 Hz and 250 Hz stimulation at P1 (Figure 6C–E). The hyperalgesia and hypersensitivity were significantly reversed by repeated Ki16425-treatments (i.p.), from P5 to P18 in donor mice (Figure 6C–E).

4. Discussion

Previous reports have shown that thermal hyperalgesia in IPGP and ICGP models are completely abolished in male LPA1-KO mice [20]. The present study evaluated the sex-dependent involvements of LPA1 and LPA3 in the IPGP model. Mechanical paw withdrawal threshold was tested using an electronic digital von Frey anesthesiometer and the electrical stimulation-induced paw withdrawal test (EPW) was performed using a Neurometer, as briefly summarized in Table 1. In the IPGP model, male LPA1- or LPA3-KO mice did not experience mechanical hyperalgesia and EPW hypersensitivity. Similar effects were observed in male LPA1- or LPA3-KO mice after systemic administration (i.p.) of Ki16425 (an LPA1/3 antagonist). In female LPA1-KO mice, mechanical hyperalgesia and EPW hypersensitivity were also absent. Whilst in LPA3-KO mice, there was no, or a very weak blocking effect, even when treated with Ki16425 (i.p.). Sexual dimorphism of LPA1/3 receptor signaling was more evident when Ki16425 was administered into the brain (i.c.v.). Repeated i.c.v. treatments with Ki16425 completely reversed the mechanical hyperalgesia and EPW hypersensitivity in male mice, but no reversal was observed in female mice. As Ki16425 (i.t.) had no effect on male and female mice, brain LPA1 and LPA3 signaling likely play key roles in the mechanisms underlying IPGP in male mice. Female LPA3 mice, in contrast, show no, or very limited contribution of LPA3 signaling. There are reports that LPA1 and LPA3 signaling are associated with activating microglia, namely for the self-amplification of LPA and production of brain-derived neurotrophic factor in the NeuP mechanisms [7,45]. All these findings are reminiscent of previous reports that NeuP is associated with microglial activation in male, but not female mice [32,33].
There have been many reports on the role of macrophages in NeuP models [46]. One experimental evidence for this can be seen in a study showing the disappearance of NeuP by using clodronate liposomes, which phagocytose activated peripheral macrophages and cause cell death via metabolic toxin clodronate [38]. In the present study, we verified the validity of this technique using the pSNL model. As reported before [47], the present study confirmed that clodronate liposome treatment abolished pSNL-induced hyperalgesia and hypersensitivity. However, clodronate liposome treatment had no effect in the IPGP model at P1 and P5. Therefore, it is evident that peripheral macrophages are not involved in IPGP mechanisms.
Accumulating studies have reported that the peripheral immune system is involved in the sexual dimorphism of NeuP mechanisms. These suggest brain microglia are involved in male, but not female mice. In female mice, the peripheral immune system, but not central, likely plays a key role in the NeuP mechanism [30,33]. To further investigate a possible involvement of the peripheral immune system, we explored the involvement of splenocytes. This was based on the analogy of our previous study, in which splenocytes derived from donor mice with chronic muscular pain induced by twice repeated acid injections, caused hyperalgesia in naïve mice [27]. The present study confirmed this speculation by finding that systemic (retro-orbital) injection of splenocytes from donor mice in the IPGP model, into naïve mice, caused significant hyperalgesia and hypersensitivity. As systemic Ki16425-treatment of female donor mice reversed the abnormal pain activity of splenocytes, peripheral LPA1/3 mechanisms are likely involved in this reversal. However, it remains unclear whether LPA1/3 signaling in splenocytes is responsible for such mechanisms. For this discussion, it is necessary to perform several key experiments in female mice treated with IPS, such as whether LPA1/3 or biosynthesis enzyme autotaxin are upregulated in splenic T-cells or B-cells. Current reports suggest that plasma cytokine levels (possibly from T-cells) in FM patients may be associated with FM development [48,49,50]. Furthermore, pain-related immunoglobulin G (IgGs) may be derived plasma cells differentiated from activated B-cells [51]. A recent study also revealed that IgGs from FM patients were accumulated in satellite glial cells, possibly leading to DRG neuron stimulation [52,53,54].
It remains unclear what mechanisms are involved in male brain-specific LPA1 and LPA3 mechanisms in the IPGP model. Future studies on male-specific microglial roles, as seen in the case of AcGP-type FM model [27], may be noteworthy. Indeed, recent studies demonstrated the male-specific expression of microglia-derived molecules, which are associated with sexually dimorphic NeuP [55,56,57]. Thus, it should be interesting to investigate whether LPA1 or LPA3 signaling is associated with the actions on these specific molecules.

5. Conclusions

In conclusion, accumulating studies demonstrated that LPA1/3 signaling plays key roles in the mechanisms underlying several NeuP and FM models [7]. The present study firstly demonstrated that there is sexual dimorphism in LPA1/3 signaling in the IPGP model. Upon i.c.v. treatment with an LPA1/3-antagonist, hyperalgesia and hypersensitivity in male, but not female mice, were abolished, although systemic treatment reversed the abnormal pain in both male and female mice. Furthermore, studies revealed that peripheral macrophages were not involved, whilst splenocytes derived from female IPGP model mice caused hyperalgesia in naïve mice. Thus, these findings advocate the necessity to identify the male-specific LPA1/3-mediated mechanisms in the brain underlying IPGP, as well as molecular-based peripheral immune mechanisms, which may contribute to the translational potential of the research, such as diagnostics and treatments by targeting involved molecules.

Author Contributions

Conceptualization, H.U.; methodology, H.U.; validation, H.N. and N.D.; formal analysis, H.N. and N.D.; investigation, H.N. and N.D.; resources, H.U.; writing—original draft preparation, H.U., H.N., J.A., and J.C.; writing—review and editing, H.U., H.N., and J.C.; supervision, H.U.; project administration, H.U.; funding acquisition, H.U. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by KAKENHI JP17H01586, JP19K21592, and JP21H03024 (HU) from the Japan Society for the Promotion of Science (JSPS), and Platform for Drug Discovery, Informatics, and Structural Life Science [16am0101012j0005] (HU) from Japan Agency for Medical Research and Development (AMED), and NSTC 113-2320-B-016-004 (HU) from NSTC (R.O.C. Taiwan).

Institutional Review Board Statement

All experiments were conducted in accordance with the ethical guidelines of the Kyoto University Animal Research Committees (Approval number: 19–38, approval date: 2019-04-01), Nagasaki University Animal Research Committees (Approval number: 1607201325-8, approval date: 20 July 2016) and complied with the fundamental guidelines for the proper conduct of animal experiments and related activities in academic research institutions under the jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology, Japan.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are available upon request to the authors.

Acknowledgments

We thank Shuji Kaneko and Hisashi Shirakawa for the help in animal studies in Kyoto University and Myles Sant-Cassia for English editing of the manuscript.

Conflicts of Interest

Author Jerold Chun has an employment relationship with Neurocrine Biosciences, a company that may potentially benefit from the research results. Jerold Chun’s relationship with Neurocrine Biosciences has been reviewed and approved by Sanford Burnham Prebys Medical Discovery Institute in accordance with its Conflict of Interest Policies. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Abbreviations

The following abbreviations are used in this manuscript:
FMFibromyalgia
ICGPIntermittent Cold Stress-Induced Generalized Pain
IPGPIntermittent Psychological Stress-Induced Generalized Pain
LPALysophosphatidic acid
NeuPNeuropathic Pain
pSNLPartial Sciatic Nerve ligation
IGGsImmunoglobulin G

References

  1. Fillingim, R.B.; King, C.D.; Ribeiro-Dasilva, M.C.; Rahim-Williams, B.; Riley, J.L., III. Sex, gender, and pain: A review of recent clinical and experimental findings. J. Pain 2009, 10, 447–485. [Google Scholar] [CrossRef]
  2. Todd, A.; McNamara, C.L.; Balaj, M.; Huijts, T.; Akhter, N.; Thomson, K.; Kasim, A.; Eikemo, T.A.; Bambra, C. The European epidemic: Pain prevalence and socioeconomic inequalities in pain across 19 European countries. Eur. J. Pain 2019, 23, 1425–1436. [Google Scholar] [CrossRef]
  3. Tsang, A.; Von Korff, M.; Lee, S.; Alonso, J.; Karam, E.; Angermeyer, M.C.; Borges, G.L.; Bromet, E.J.; Demytteneare, K.; de Girolamo, G.; et al. Common chronic pain conditions in developed and developing countries: Gender and age differences and comorbidity with depression-anxiety disorders. J. Pain 2008, 9, 883–891. [Google Scholar] [CrossRef]
  4. Zimmer, Z.; Fraser, K.; Grol-Prokopczyk, H.; Zajacova, A. A global study of pain prevalence across 52 countries: Examining the role of country-level contextual factors. Pain 2022, 163, 1740–1750. [Google Scholar] [CrossRef]
  5. Inoue, M.; Rashid, M.H.; Fujita, R.; Contos, J.J.; Chun, J.; Ueda, H. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat. Med. 2004, 10, 712–718. [Google Scholar] [CrossRef]
  6. Ueda, H. Lysophosphatidic acid signaling is the definitive mechanism underlying neuropathic pain. Pain 2017, 158 (Suppl. S1), S55–S65. [Google Scholar] [CrossRef]
  7. Ueda, H. Pathogenic mechanisms of lipid mediator lysophosphatidic acid in chronic pain. Prog. Lipid Res. 2021, 81, 101079. [Google Scholar] [CrossRef]
  8. Uranbileg, B.; Ito, N.; Kurano, M.; Saigusa, D.; Saito, R.; Uruno, A.; Kano, K.; Ikeda, H.; Yamada, Y.; Sumitani, M.; et al. Alteration of the lysophosphatidic acid and its precursor lysophosphatidylcholine levels in spinal cord stenosis: A study using a rat cauda equina compression model. Sci. Rep. 2019, 9, 16578. [Google Scholar] [CrossRef]
  9. Ahn, D.K.; Lee, S.Y.; Han, S.R.; Ju, J.S.; Yang, G.Y.; Lee, M.K.; Youn, D.H.; Bae, Y.C. Intratrigeminal ganglionic injection of LPA causes neuropathic pain-like behavior and demyelination in rats. Pain 2009, 146, 114–120. [Google Scholar] [CrossRef]
  10. McDougall, J.J.; Albacete, S.; Schuelert, N.; Mitchell, P.G.; Lin, C.; Oskins, J.L.; Bui, H.H.; Chambers, M.G. Lysophosphatidic acid provides a missing link between osteoarthritis and joint neuropathic pain. Osteoarthr. Cartil. 2017, 25, 926–934. [Google Scholar] [CrossRef]
  11. O’Brien, M.S.; Philpott, H.T.A.; McDougall, J.J. Targeting the Nav1.8 ion channel engenders sex-specific responses in lysophosphatidic acid-induced joint neuropathy. Pain 2019, 160, 269–278. [Google Scholar] [CrossRef]
  12. Ueda, H.; Neyama, H.; Nagai, J.; Matsushita, Y.; Tsukahara, T.; Tsukahara, R. Involvement of lysophosphatidic acid-induced astrocyte activation underlying the maintenance of partial sciatic nerve injury-induced neuropathic pain. Pain 2018, 159, 2170–2178. [Google Scholar] [CrossRef]
  13. Edamura, T.; Sumitani, M.; Hayakawa, K.; Inoue, R.; Abe, H.; Tsuchida, R.; Chikuda, H.; Ogata, T.; Kurano, M.; Aoki, J.; et al. Different Profiles of the Triad of Lysophosphatidylcholine, Lysophosphatidic Acid, and Autotaxin in Patients with Neuropathic Pain Diseases: A Preliminary Observational Study. Pain Ther. 2022, 11, 1439–1449. [Google Scholar] [CrossRef]
  14. Velasco, M.; O’Sullivan, C.; Sheridan, G.K. Lysophosphatidic acid receptors (LPARs): Potential targets for the treatment of neuropathic pain. Neuropharmacology 2017, 113, 608–617. [Google Scholar] [CrossRef]
  15. Khasar, S.G.; Miao, F.J.; Janig, W.; Levine, J.D. Vagotomy-induced enhancement of mechanical hyperalgesia in the rat is sympathoadrenal-mediated. J. Neurosci. 1998, 18, 3043–3049. [Google Scholar] [CrossRef]
  16. Sluka, K.A.; Kalra, A.; Moore, S.A. Unilateral intramuscular injections of acidic saline produce a bilateral, long-lasting hyperalgesia. Muscle Nerve 2001, 24, 37–46. [Google Scholar] [CrossRef]
  17. Nishiyori, M.; Ueda, H. Prolonged gabapentin analgesia in an experimental mouse model of fibromyalgia. Mol. Pain 2008, 4, 52. [Google Scholar] [CrossRef]
  18. Khasar, S.G.; Dina, O.A.; Green, P.G.; Levine, J.D. Sound stress-induced long-term enhancement of mechanical hyperalgesia in rats is maintained by sympathoadrenal catecholamines. J. Pain 2009, 10, 1073–1077. [Google Scholar] [CrossRef]
  19. Nagakura, Y.; Oe, T.; Aoki, T.; Matsuoka, N. Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia. Pain 2009, 146, 26–33. [Google Scholar] [CrossRef]
  20. Ueda, H.; Neyama, H. LPA1 receptor involvement in fibromyalgia-like pain induced by intermittent psychological stress, empathy. Neurobiol. Pain 2017, 1, 16–25. [Google Scholar] [CrossRef]
  21. Ueda, H.; Neyama, H. Fibromyalgia Animal Models Using Intermittent Cold and Psychological Stress. Biomedicines 2023, 12, 56. [Google Scholar] [CrossRef]
  22. Amaral, R.F.; Geraldo, L.H.M.; Einicker-Lamas, M.; TCLS, E.S.; Mendes, F.; Lima, F.R.S. Microglial lysophosphatidic acid promotes glioblastoma proliferation and migration via LPA1 receptor. J. Neurochem. 2021, 156, 499–512. [Google Scholar] [CrossRef]
  23. Gaire, B.P.; Choi, J.W. Critical Roles of Lysophospholipid Receptors in Activation of Neuroglia and Their Neuroinflammatory Responses. Int. J. Mol. Sci. 2021, 22, 7864. [Google Scholar] [CrossRef]
  24. Gaire, B.P.; Sapkota, A.; Song, M.R.; Choi, J.W. Lysophosphatidic acid receptor 1 (LPA1) plays critical roles in microglial activation and brain damage after transient focal cerebral ischemia. J. Neuroinflamm. 2019, 16, 170. [Google Scholar] [CrossRef]
  25. Kwon, J.H.; Gaire, B.P.; Park, S.J.; Shin, D.Y.; Choi, J.W. Identifying lysophosphatidic acid receptor subtype 1 (LPA1) as a novel factor to modulate microglial activation and their TNF-α production by activating ERK1/2. Biochim. Biophys. Acta. Mol. Cell Biol. Lipids 2018, 1863, 1237–1245. [Google Scholar] [CrossRef]
  26. Plastira, I.; Bernhart, E.; Joshi, L.; Koyani, C.N.; Strohmaier, H.; Reicher, H.; Malle, E.; Sattler, W. MAPK signaling determines lysophosphatidic acid (LPA)-induced inflammation in microglia. J. Neuroinflamm. 2020, 17, 127. [Google Scholar] [CrossRef]
  27. Ueda, H.; Dozono, N.; Tanaka, K.; Kaneko, S.; Neyama, H.; Uchida, H. Allodynia by Splenocytes from Mice with Acid-Induced Fibromyalgia-Like Generalized Pain and Its Sexual Dimorphic Regulation by Brain Microglia. Front. Neurosci. 2020, 14, 600166. [Google Scholar] [CrossRef]
  28. Boerner, K.E.; Chambers, C.T.; Gahagan, J.; Keogh, E.; Fillingim, R.B.; Mogil, J.S. Conceptual complexity of gender and its relevance to pain. Pain 2018, 159, 2137–2141. [Google Scholar] [CrossRef]
  29. Mapplebeck, J.C.; Beggs, S.; Salter, M.W. Molecules in pain and sex: A developing story. Mol. Brain 2017, 10, 9. [Google Scholar] [CrossRef]
  30. Mapplebeck, J.C.S.; Beggs, S.; Salter, M.W. Sex differences in pain: A tale of two immune cells. Pain 2016, 157 (Suppl. S1), S2–S6. [Google Scholar] [CrossRef]
  31. Mogil, J.S. Qualitative sex differences in pain processing: Emerging evidence of a biased literature. Nat. Rev. Neurosci. 2020, 21, 353–365. [Google Scholar] [CrossRef]
  32. Sorge, R.E.; LaCroix-Fralish, M.L.; Tuttle, A.H.; Sotocinal, S.G.; Austin, J.S.; Ritchie, J.; Chanda, M.L.; Graham, A.C.; Topham, L.; Beggs, S.; et al. Spinal cord Toll-like receptor 4 mediates inflammatory and neuropathic hypersensitivity in male but not female mice. J. Neurosci. 2011, 31, 15450–15454. [Google Scholar] [CrossRef]
  33. Sorge, R.E.; Mapplebeck, J.C.; Rosen, S.; Beggs, S.; Taves, S.; Alexander, J.K.; Martin, L.J.; Austin, J.S.; Sotocinal, S.G.; Chen, D.; et al. Different immune cells mediate mechanical pain hypersensitivity in male and female mice. Nat. Neurosci. 2015, 18, 1081–1083. [Google Scholar] [CrossRef]
  34. Contos, J.J.; Fukushima, N.; Weiner, J.A.; Kaushal, D.; Chun, J. Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc. Natl. Acad. Sci. USA 2000, 97, 13384–13389. [Google Scholar] [CrossRef]
  35. Ye, X.; Hama, K.; Contos, J.J.; Anliker, B.; Inoue, A.; Skinner, M.K.; Suzuki, H.; Amano, T.; Kennedy, G.; Arai, H.; et al. LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature 2005, 435, 104–108. [Google Scholar] [CrossRef]
  36. du Sert, N.P.; Hurst, V.; Ahluwalia, A.; Alam, S.; Avey, M.T.; Baker, M.; Browne, W.J.; Clark, A.; Cuthill, I.C.; Dirnagl, U.; et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. Br. J. Pharmacol. 2020, 177, 3617–3624. [Google Scholar] [CrossRef]
  37. Koga, K.; Furue, H.; Rashid, M.H.; Takaki, A.; Katafuchi, T.; Yoshimura, M. Selective activation of primary afferent fibers evaluated by sine-wave electrical stimulation. Mol. Pain 2005, 1, 13. [Google Scholar] [CrossRef]
  38. Nguyen, T.; Du, J.; Li, Y.C. A protocol for macrophage depletion and reconstitution in a mouse model of sepsis. STAR Protoc. 2021, 2, 101004. [Google Scholar] [CrossRef]
  39. Yamashita, S.; Dozono, N.; Tobori, S.; Nagayasu, K.; Kaneko, S.; Shirakawa, H.; Ueda, H. Peripheral Beta-2 Adrenergic Receptors Mediate the Sympathetic Efferent Activation from Central Nervous System to Splenocytes in a Mouse Model of Fibromyalgia. Int. J. Mol. Sci. 2023, 24, 3465. [Google Scholar] [CrossRef]
  40. Yardeni, T.; Eckhaus, M.; Morris, H.D.; Huizing, M.; Hoogstraten-Miller, S. Retro-orbital injections in mice. Lab Anim. 2011, 40, 155–160. [Google Scholar] [CrossRef]
  41. University Animal Care Committee Standard Operating Procedure. Available online: https://www.queensu.ca/animals-in-science/policies-procedures/sop/mice/7-11 (accessed on 3 July 2025).
  42. Haley, T.J.; McCormick, W.G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br. J. Pharmacol. Chemother. 1957, 12, 12–15. [Google Scholar] [CrossRef]
  43. Hylden, J.L.; Wilcox, G.L. Intrathecal morphine in mice: A new technique. Eur. J. Pharmacol. 1980, 67, 313–316. [Google Scholar] [CrossRef]
  44. Matsumoto, M.; Xie, W.; Ma, L.; Ueda, H. Pharmacological switch in Aβ-fiber stimulation-induced spinal transmission in mice with partial sciatic nerve injury. Mol. Pain 2008, 4, 25. [Google Scholar] [CrossRef]
  45. Ma, L.; Nagai, J.; Ueda, H. Microglial activation mediates de novo lysophosphatidic acid production in a model of neuropathic pain. J. Neurochem. 2010, 115, 643–653. [Google Scholar] [CrossRef]
  46. Kiguchi, N.; Kobayashi, D.; Saika, F.; Matsuzaki, S.; Kishioka, S. Pharmacological Regulation of Neuropathic Pain Driven by Inflammatory Macrophages. Int. J. Mol. Sci. 2017, 18, 2296. [Google Scholar] [CrossRef]
  47. Liu, T.; van Rooijen, N.; Tracey, D.J. Depletion of macrophages reduces axonal degeneration and hyperalgesia following nerve injury. Pain 2000, 86, 25–32. [Google Scholar] [CrossRef]
  48. Ellergezen, P.; Alp, A.; Cavun, S.; Celebi, M.; Macunluoglu, A.C. Pregabalin inhibits proinflammatory cytokine release in patients with fibromyalgia syndrome. Arch. Rheumatol. 2023, 38, 307–314. [Google Scholar] [CrossRef]
  49. Gerdle, B.; Leinhard, O.D.; Lund, E.; Lundberg, P.; Forsgren, M.F.; Ghafouri, B. Pain and the biochemistry of fibromyalgia: Patterns of peripheral cytokines and chemokines contribute to the differentiation between fibromyalgia and controls and are associated with pain, fat infiltration and content. Front. Pain Res. 2024, 5, 1288024. [Google Scholar] [CrossRef]
  50. Peck, M.M.; Maram, R.; Mohamed, A.; Crespo, D.O.; Kaur, G.; Ashraf, I.; Malik, B.H. The Influence of Pro-inflammatory Cytokines and Genetic Variants in the Development of Fibromyalgia: A Traditional Review. Cureus 2020, 12, e10276. [Google Scholar] [CrossRef]
  51. Goebel, A.; Krock, E.; Gentry, C.; Israel, M.R.; Jurczak, A.; Urbina, C.M.; Sandor, K.; Vastani, N.; Maurer, M.; Cuhadar, U.; et al. Passive transfer of fibromyalgia symptoms from patients to mice. J. Clin. Investig. 2021, 131, e144201. [Google Scholar] [CrossRef]
  52. Fanton, S.; Menezes, J.; Krock, E.; Sandstrom, A.; Tour, J.; Sandor, K.; Jurczak, A.; Hunt, M.; Baharpoor, A.; Kadetoff, D.; et al. Anti-satellite glia cell IgG antibodies in fibromyalgia patients are related to symptom severity and to metabolite concentrations in thalamus and rostral anterior cingulate cortex. Brain Behav. Immun. 2023, 114, 371–382. [Google Scholar] [CrossRef]
  53. Jakobsson, J.E.; Menezes, J.; Krock, E.; Hunt, M.A.; Carlsson, H.; Vaivade, A.; Khoonsari, P.E.; Agalave, N.M.; Sandstrom, A.; Kadetoff, D.; et al. Fibromyalgia patients have altered lipid concentrations associated with disease symptom severity and anti-satellite glial cell IgG antibodies. J. Pain 2025, 29, 105331. [Google Scholar] [CrossRef]
  54. Krock, E.; Morado-Urbina, C.E.; Menezes, J.; Hunt, M.A.; Sandstrom, A.; Kadetoff, D.; Tour, J.; Verma, V.; Kultima, K.; Haglund, L.; et al. Fibromyalgia patients with elevated levels of anti-satellite glia cell immunoglobulin G antibodies present with more severe symptoms. Pain 2023, 164, 1828–1840. [Google Scholar] [CrossRef]
  55. Fan, C.Y.; McAllister, B.B.; Stokes-Heck, S.; Harding, E.K.; de Vasconcelos, A.P.; Mah, L.K.; Lima, L.V.; van den Hoogen, N.J.; Rosen, S.F.; Ham, B.; et al. Divergent sex-specific pannexin-1 mechanisms in microglia and T cells underlie neuropathic pain. Neuron 2025, 113, 896–911.e899. [Google Scholar] [CrossRef]
  56. Lister, K.C.; Wong, C.; Cai, W.; Uttam, S.; Stecum, P.; Rodrigues, R.; Hooshmandi, M.; Brown, N.; Fan, J.; Francois-Saint-Cyr, N.; et al. 4E-BP1-dependent translation in microglia controls mechanical hypersensitivity in male and female mice. J. Clin. Investig. 2025, 135, e180190. [Google Scholar] [CrossRef]
  57. Saika, F.; Sato, T.; Nakabayashi, T.; Fukazawa, Y.; Hino, S.; Suzuki, K.; Kiguchi, N. Male-Dominant Spinal Microglia Contribute to Neuropathic Pain by Producing CC-Chemokine Ligand 4 Following Peripheral Nerve Injury. Cells 2025, 14, 484. [Google Scholar] [CrossRef]
Cells 14 01022 g001
Figure 1. Reversal of male IPGP and ICGP by genetic deletion of LPA3 or repeated i.p. treatments with LPA1/3 antagonist. (A) Illustrative diagram of intermittent psychological stress (IPS)-induced generalized pain (IPGP) model. (B) Reversal of IPS-induced mechanical hyperalgesia by genetic deficiency of LPA3 in male mice. Mechanical hyperalgesia at P1–P22 was observed in the paw withdrawal test. (C) Illustrative diagram of intermittent cold stress (ICS)-induced generalized pain (ICGP) model. (D) Reversal of ICS-induced mechanical hyperalgesia (P1–P19) by genetic deficiency of LPA3 in male mice. (E) Schedule of IPS-treatments and systemic (i.p.)-treatments with Ki16425. (F–H) Time-dependent change in threshold in the IPGP model treated with vehicle or Ki16425 in the paw pressure test (F), EPW 2000 Hz (G), and EPW 250 Hz (H). (B) ** p < 0.01, two-way ANOVA followed by Tukey’s multiple comparisons test (WT-Cont, n = 6; WT-IPS, n = 6; LPA3-KO-Cont, n = 4; LPA3-KO-IPS, n = 5). (D) ** p < 0.01, two-way ANOVA, followed by Tukey’s multiple comparisons test (WT-Cont, n = 3; WT-ICS, n = 3; LPA3-KO-Cont, n = 7; LPA3-KO-ICS, n = 7). (F–H) ** p < 0.01, **** p < 0.0001, two-way ANOVA followed by Bonferroni’s multiple comparisons test (Veh, n = 3–4; Ki16425, n = 4).
Figure 1. Reversal of male IPGP and ICGP by genetic deletion of LPA3 or repeated i.p. treatments with LPA1/3 antagonist. (A) Illustrative diagram of intermittent psychological stress (IPS)-induced generalized pain (IPGP) model. (B) Reversal of IPS-induced mechanical hyperalgesia by genetic deficiency of LPA3 in male mice. Mechanical hyperalgesia at P1–P22 was observed in the paw withdrawal test. (C) Illustrative diagram of intermittent cold stress (ICS)-induced generalized pain (ICGP) model. (D) Reversal of ICS-induced mechanical hyperalgesia (P1–P19) by genetic deficiency of LPA3 in male mice. (E) Schedule of IPS-treatments and systemic (i.p.)-treatments with Ki16425. (F–H) Time-dependent change in threshold in the IPGP model treated with vehicle or Ki16425 in the paw pressure test (F), EPW 2000 Hz (G), and EPW 250 Hz (H). (B) ** p < 0.01, two-way ANOVA followed by Tukey’s multiple comparisons test (WT-Cont, n = 6; WT-IPS, n = 6; LPA3-KO-Cont, n = 4; LPA3-KO-IPS, n = 5). (D) ** p < 0.01, two-way ANOVA, followed by Tukey’s multiple comparisons test (WT-Cont, n = 3; WT-ICS, n = 3; LPA3-KO-Cont, n = 7; LPA3-KO-ICS, n = 7). (F–H) ** p < 0.01, **** p < 0.0001, two-way ANOVA followed by Bonferroni’s multiple comparisons test (Veh, n = 3–4; Ki16425, n = 4).
Cells 14 01022 g001
Cells 14 01022 g002
Figure 2. Reversal of female IPGP by genetic deletion of LPA1/3 or repeated i.p. treatments with Ki16425. (A) Schedule of IPS-treatments and systemic (i.p.)-treatments with Ki16425. (B–D) Time-dependent reversal of IPS-induced mechanical hyperalgesia (B) and hypersensitivity in EPW tests with 2000 Hz (C) or 250 Hz (D) by genetic deficiency of LPA1 or LPA3, or by Ki16425 (i.p.) in female mice. (B–D) * p < 0.05, ** p < 0.01, **** p < 0.0001, Veh vs. Ki16425 (0–19), and two-way ANOVA followed by Bonferroni’s multiple comparisons test (Veh, n = 4–6; Ki16425, n = 4–6). $ p < 0.05, $$ p < 0.01, $$$ p < 0.001, $$$$ p < 0.0001, n.s.; not significant, Veh vs. LPA1-KO or LPA3-KO, nd two-way ANOVA followed by Tukey’s multiple comparisons test (0–5; Veh, n = 4–6; LPA1-KO, n = 4; LPA3-KO, n = 4).
Figure 2. Reversal of female IPGP by genetic deletion of LPA1/3 or repeated i.p. treatments with Ki16425. (A) Schedule of IPS-treatments and systemic (i.p.)-treatments with Ki16425. (B–D) Time-dependent reversal of IPS-induced mechanical hyperalgesia (B) and hypersensitivity in EPW tests with 2000 Hz (C) or 250 Hz (D) by genetic deficiency of LPA1 or LPA3, or by Ki16425 (i.p.) in female mice. (B–D) * p < 0.05, ** p < 0.01, **** p < 0.0001, Veh vs. Ki16425 (0–19), and two-way ANOVA followed by Bonferroni’s multiple comparisons test (Veh, n = 4–6; Ki16425, n = 4–6). $ p < 0.05, $$ p < 0.01, $$$ p < 0.001, $$$$ p < 0.0001, n.s.; not significant, Veh vs. LPA1-KO or LPA3-KO, nd two-way ANOVA followed by Tukey’s multiple comparisons test (0–5; Veh, n = 4–6; LPA1-KO, n = 4; LPA3-KO, n = 4).
Cells 14 01022 g002
Cells 14 01022 g003
Figure 3. Male-specific reversal of hyperalgesia and hypersensitivity by repeated i.c.v. treatments with Ki16425. (A) Schedule of IPS-treatments and repeated i.c.v. treatments with Ki16425. (B–D) Reversal of IPS-induced mechanical hyperalgesia (B) and hypersensitivity in EPW tests with 2000 Hz (C) or 250 Hz (D) by Ki16425 (i.c.v.)-treatments in male mice. (E–G) Lack of reversal of IPS-induced mechanical hyperalgesia (E) and hypersensitivity in EPW tests with 2000 Hz (F) or 250 Hz (G) by Ki16425 (i.c.v.)-treatments in female mice. (B–G) ** p < 0.01, *** p < 0.001, **** p < 0.0001, n.s.; not significant, and two-way ANOVA followed by Bonferroni’s multiple comparisons test (male Veh, n = 4; female Veh, n = 5; Ki16425, n = 4).
Figure 3. Male-specific reversal of hyperalgesia and hypersensitivity by repeated i.c.v. treatments with Ki16425. (A) Schedule of IPS-treatments and repeated i.c.v. treatments with Ki16425. (B–D) Reversal of IPS-induced mechanical hyperalgesia (B) and hypersensitivity in EPW tests with 2000 Hz (C) or 250 Hz (D) by Ki16425 (i.c.v.)-treatments in male mice. (E–G) Lack of reversal of IPS-induced mechanical hyperalgesia (E) and hypersensitivity in EPW tests with 2000 Hz (F) or 250 Hz (G) by Ki16425 (i.c.v.)-treatments in female mice. (B–G) ** p < 0.01, *** p < 0.001, **** p < 0.0001, n.s.; not significant, and two-way ANOVA followed by Bonferroni’s multiple comparisons test (male Veh, n = 4; female Veh, n = 5; Ki16425, n = 4).
Cells 14 01022 g003
Cells 14 01022 g004
Figure 4. Lack of reversal of hyperalgesia and hypersensitivity by i.t. treatments with Ki16425. (A) Schedule of IPS-treatments and repeated i.t. treatments with Ki16425. (B–G) Lack of reversal of IPS-induced mechanical hyperalgesia (B,E) and hypersensitivity in EPW tests with 2000 Hz (C,F) or 250 Hz (D,G) by Ki16425 (i.t.)-treatments in male (B–D) and female mice (E–G). (B–G) n.s.; not significant and two-way ANOVA followed by Bonferroni’s multiple comparisons test (male Veh, n = 4; female Veh, n = 4–8; Ki16425, n = 4–8).
Figure 4. Lack of reversal of hyperalgesia and hypersensitivity by i.t. treatments with Ki16425. (A) Schedule of IPS-treatments and repeated i.t. treatments with Ki16425. (B–G) Lack of reversal of IPS-induced mechanical hyperalgesia (B,E) and hypersensitivity in EPW tests with 2000 Hz (C,F) or 250 Hz (D,G) by Ki16425 (i.t.)-treatments in male (B–D) and female mice (E–G). (B–G) n.s.; not significant and two-way ANOVA followed by Bonferroni’s multiple comparisons test (male Veh, n = 4; female Veh, n = 4–8; Ki16425, n = 4–8).
Cells 14 01022 g004
Cells 14 01022 g005
Figure 5. Lack of reversal of IPS-induced hyperalgesia and hypersensitivity by clodronate liposome in the IPGP model. (A) Illustrative diagram of partial sciatic nerve injury (pSNL) model. (B) Schedule of clodronate treatments and pain tests in the partial sciatic nerve injury (pSNL) model in male mice. (C–E) Reversal of pSNL-induced mechanical hyperalgesia (C) or hypersensitivity in the EPW 2000 Hz (D) or 250 Hz (E) tests by clodronate liposome treatments. (F) Illustrative diagram of IPGP model. (G) Schedule of clodronate treatments and pain tests in the IPGP model in female mice. (H–J) Lack of reversal of the IPS-induced hyperalgesia (H) or hypersensitivity (I,J) by clodronate liposome treatments. (C–E) * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and two-way ANOVA followed by Tukey’s multiple comparisons test (contra-Veh, n = 4; ipsi-Veh, n = 4; contra-Clodronate, n = 3–4; ipsi-Clodronate, n = 3–4). (H–J) n.s.; not significant and two-way ANOVA followed by Bonferroni’s multiple comparisons test (Veh, n = 4–6; Clodronate, n = 4–6).
Figure 5. Lack of reversal of IPS-induced hyperalgesia and hypersensitivity by clodronate liposome in the IPGP model. (A) Illustrative diagram of partial sciatic nerve injury (pSNL) model. (B) Schedule of clodronate treatments and pain tests in the partial sciatic nerve injury (pSNL) model in male mice. (C–E) Reversal of pSNL-induced mechanical hyperalgesia (C) or hypersensitivity in the EPW 2000 Hz (D) or 250 Hz (E) tests by clodronate liposome treatments. (F) Illustrative diagram of IPGP model. (G) Schedule of clodronate treatments and pain tests in the IPGP model in female mice. (H–J) Lack of reversal of the IPS-induced hyperalgesia (H) or hypersensitivity (I,J) by clodronate liposome treatments. (C–E) * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and two-way ANOVA followed by Tukey’s multiple comparisons test (contra-Veh, n = 4; ipsi-Veh, n = 4; contra-Clodronate, n = 3–4; ipsi-Clodronate, n = 3–4). (H–J) n.s.; not significant and two-way ANOVA followed by Bonferroni’s multiple comparisons test (Veh, n = 4–6; Clodronate, n = 4–6).
Cells 14 01022 g005
Cells 14 01022 g006
Figure 6. Abnormal pain by splenocytes derived from IPS-treated mice. (A) Schedule of IPS treatments and repeated i.p. treatments with Ki16425 in female donor mice. (B) Experimental procedure for splenocytes injection. (C–E) Ki16425-reversible hyperalgesia (B) and hypersensitivity (C,D) in naïve female mice by adoptive transfer of splenocytes from IPS-treated donor female mice. Ki16425 (i.p.) was treated in donor mice, as described in the legend of Figure 3. (C–D) **** p < 0.0001 and two-way ANOVA followed by Tukey’s multiple comparisons test (n = 4).
Figure 6. Abnormal pain by splenocytes derived from IPS-treated mice. (A) Schedule of IPS treatments and repeated i.p. treatments with Ki16425 in female donor mice. (B) Experimental procedure for splenocytes injection. (C–E) Ki16425-reversible hyperalgesia (B) and hypersensitivity (C,D) in naïve female mice by adoptive transfer of splenocytes from IPS-treated donor female mice. Ki16425 (i.p.) was treated in donor mice, as described in the legend of Figure 3. (C–D) **** p < 0.0001 and two-way ANOVA followed by Tukey’s multiple comparisons test (n = 4).
Cells 14 01022 g006
Table 1. Summary of LPA1 and LPA3-mediated hyperalgesia and hypersensitivity.
Table 1. Summary of LPA1 and LPA3-mediated hyperalgesia and hypersensitivity.
IPS ModelSexHyperalgesia
(Paw Pressure)		Hypersensitivity
(2000 Hz)		Hypersensitivity
(250 Hz)
LPA1-KOMale− (1)No dataNo data
Female−−−
LPA3-KOMale− (2)No dataNo data
Female−−−
WT
Ki 16425, i.p.		Male−−−
Female−−−
WT
Ki 1642, i.c.v.		Male−−−
Female+++
WT
Ki 16425, i.t.		Male+++
Female+++
(1): Data have been reported elsewhere [20]. (2): The blockade of hyperalgesia was also observed in the ICS model.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Ueda, H.; Neyama, H.; Dozono, N.; Aoki, J.; Chun, J. Hyperalgesia in the Psychological Stress-Induced Fibromyalgia Model Shows Sexual Dimorphism Mediated by LPA1 and LPA3. Cells 2025, 14, 1022. https://doi.org/10.3390/cells14131022

AMA Style

Ueda H, Neyama H, Dozono N, Aoki J, Chun J. Hyperalgesia in the Psychological Stress-Induced Fibromyalgia Model Shows Sexual Dimorphism Mediated by LPA1 and LPA3. Cells. 2025; 14(13):1022. https://doi.org/10.3390/cells14131022

Chicago/Turabian Style

Ueda, Hiroshi, Hiroyuki Neyama, Naoki Dozono, Junken Aoki, and Jerold Chun. 2025. "Hyperalgesia in the Psychological Stress-Induced Fibromyalgia Model Shows Sexual Dimorphism Mediated by LPA1 and LPA3" Cells 14, no. 13: 1022. https://doi.org/10.3390/cells14131022

APA Style

Ueda, H., Neyama, H., Dozono, N., Aoki, J., & Chun, J. (2025). Hyperalgesia in the Psychological Stress-Induced Fibromyalgia Model Shows Sexual Dimorphism Mediated by LPA1 and LPA3. Cells, 14(13), 1022. https://doi.org/10.3390/cells14131022

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop